WAYNE, Pa.--(BUSINESS WIRE)--April 20, 2006--Covalent Group, Inc. (Nasdaq: CVGR - News), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world’s leading pharmaceutical and biotechnology companies, announced today the signing of a $1.0 million contract for a Phase 1 study of a potentially very important agent to prevent/treat infectious disease. Covalent will provide consulting services, clinical operations support, and Phase 1 Unit oversight for the trial. Revenue recognition, which will begin immediately, will occur on a proportional performance basis over the next several quarters.
